Press Release

AOP Health Presents Final Results From Its CONTINUATION-PV Study – up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients – at EHA 2022 Annual Meeting